Fierce Pharma May 3, 2024
During the Q&A portion of Amgen’s quarterly conference call Thursday, eight of the first nine questions were about the company’s investigational efforts in obesity.
The buzz about Amgen’s pipeline—and specifically about its promising weight loss therapy MariTide—overshadowed the company’s solid work on the top line, where revenue came in at $7.4 billion. It was a 22% increase on the $6.1 billion in sales the company achieved in the first quarter of last year.
Much of the boost can be attributed to sales of products acquired in Amgen’s $27.8 billion buyout of Horizon Therapeutics, which was completed early in the fourth quarter of last year. Assets brought by Horizon accounted for sales of $914 million, a 10% increase on the $832...
Today's Sponsors
Today's Sponsor